GPR35 and inflammatory bowel disease: As noted earlier, there is considerable interest in assessing GPR35 as a therapeutic target in inflammatory bowel diseases because in Dextran Sodium Sulphate (DSS)-induced mouse models of colitis, activation of GPR35 is generally beneficial (17, 24, 26, 27), although such conclusions are not universal (28).